Evaluation of the Implementation and Effectiveness of IPP-HPV

NACompletedINTERVENTIONAL
Enrollment

817

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
HPV Vaccination
Interventions
DRUG

HPV vaccine

After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.

BEHAVIORAL

Inpatient Postpartum HPV Immunization Quality Improvement Program

"The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.~Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.~All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed."

Trial Locations (1)

06520

Yale New Haven Hospital, Women's Center, New Haven

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Yale University

OTHER

NCT02994290 - Evaluation of the Implementation and Effectiveness of IPP-HPV | Biotech Hunter | Biotech Hunter